Progress of Dual Action Tumor Immune Agonists to Produce a Durable Clinical Response for Treatment of Solid Tumors
Time: 3:00 pm
day: Conference Day 2
Details:
- Harnessing the viability of tumor cells to produce cytokines that activate the innate immune system
- Modulating the potency and half-life of immune agonists for optimized antitumor efficacy and systematic tolerability
- Providing tumor neoatigens in situ to guide development of the emerging adaptive immune system
- Tipping the balance and break down barriers in the microenvironment of solid tumors to improve the activity and infiltration of immune cells
